Saint Laurent, Quebec--(Newsfile Corp. - February 15, 2012) - IntelGenx Corp. (TSXV: IGX) (OTCBB: IGXT) ("IntelGenx") today announced that it has been named as one of the TSX Venture 50® companies for 2012, an annual ranking of Canada’s top 50 emerging publicly traded companies. The TSX Venture 50® includes the top 10 companies in 5 major industry sectors that have been identified as leaders in providing shareholder value on Canada’s junior stock exchange. IntelGenx was ranked second in the list of ten leading Canadian Technology and Life Sciences companies for the year.
“With more than 2,000 companies listed on the TSX Venture Exchange, we are honoured to receive this award and to be named as one of the TSX Venture Top 50 companies,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “2011 was a defining year for IntelGenx, highlighted by our first FDA approval on the world's first approved high dose bupropion hydrochloride tablet. We quickly followed that up with a partnership with Par Pharmaceuticals on an undisclosed compound. We have carried that momentum forward in 2012 by adding a new commercial collaboration with Edgemont Pharmaceuticals on our recently approved drug. We are extremely excited about our pipeline of proprietary thin film products and its platform technology, so it is rewarding to be acknowledged for these accomplishments by the TSX Venture and the Canadian investment community.”
The TSX Venture 50® are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors — mining, oil & gas, technology & life sciences, diversified industries and clean technology — based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2011.
IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. IntelGenx uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. IntelGenx' research and development pipeline includes products for the treatment of severe depression, hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, bipolar disorder, idiopathic pulmonary fibrosis, allergies and pain management. More information is available about the company at www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about IntelGenx' operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx' plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx' actual results could differ materially from those expressed or implied by these forward looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx' annual report on Form 10-K for the fiscal year ended December 31, 2010, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities and www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.
Each of the TSX Venture Exchange and OTC Bulletin Board has neither approved nor disapproved the contents of this press release.
Dr. Horst G. Zerbe,
President and CEO
IntelGenx Technologies Corp.
T: +1 514-331-7440 (ext. 201)
F: +1 514-331-0436